Compare Sana Biotechnology Inc (SANA) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs DENTSPLY SIRONA Inc — how do they compare? Sana Biotechnology Inc trades at $3.19 (market cap $947.48M), while DENTSPLY SIRONA Inc trades at $10.7 (market cap $2.14B). The key difference: DENTSPLY SIRONA Inc is far larger — about 2.3× Sana Biotechnology Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | XRAY | |
|---|---|---|
Market Cap | $947.48M | $2.14B |
Sector | Health | Health |
52-Week High | $5.92 | $14.68 |
52-Week Low | $2.68 | $9.64 |
Enterprise Value | $860.73M | $4.21B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $244.17 million for 2025, with ROE at -152.87%. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data for type 1 diabetes treatment.
Analyst consensus is strongly bullish with 81.82% buy ratings, but high cash burn and negative earnings pose significant risks. Upside potential hinges on clinical success and future profitability, while downside risks include sustained losses and competitive pressures in biotechnology.
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing pressure from declining revenues and negative profitability. The stock shows a bearish technical signal, with key support at $10. Recent Q2 2026 earnings beat estimates but sales fell 4.1%, highlighting persistent challenges in dental markets. Cash flow improved in 2025, yet net losses and high debt levels remain concerns.
The outlook is cautious; while analyst consensus suggests modest upside to a $12.50 target, weak margins, falling sales, and potential fiduciary scrutiny pose significant risks. Recovery depends on successful execution of the company's turnaround plan amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
